![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
林沃塞尔塔马布,BCMA导向的CD3T细胞参与多发性骨髓瘤:通过响应调整的剂量方案,以患者为中心的选择?
Jacob A Lowy1, Michael F Rogers1, Zachary M Avigan1
1Icahn School of Medicine at Mount Sinai, NY , USA.
Expert review of hematology
|February 18, 2026
概括
林沃塞尔塔马布是一种新的双特异性T细胞参与剂 (BiTE),对复发性或耐火性多发性髓瘤 (RRMM) 患者表现有前途. 与其他治疗方法相比,它具有可比的疗效和有利的副作用概况.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤 (MM) 的治疗需要新的方法来实现持久的缓解.
- 针对BCMA的双特异性T细胞诱导剂 (BiTEs) 在晚期MM中显示出有效性.
- 林沃塞尔塔马布是一种新的BCMAxCD3双特异抗体,最近被批准用于RRMM.
研究的目的:
- 审查linvoseltamab的作用机制 (MOA),药理动力学,疗效和毒性.
- 为了将林沃塞尔塔马布与其他已批准的BTE和BCMA导向疗法进行比较.
- 为了突出linvoseltamab的剂量和副作用概况.
主要方法:
- 讨论MOA,药理动力学,疗效和毒性.
- 与其他已批准的BTE和BCMA导向疗法进行比较.
- 对间接疗效比较的审查.间接疗效比较的审查.
主要成果:
- 林沃塞尔塔马布是第四个经过≥4线治疗后被批准用于RRMM的双特异抗体.
- 交叉试验比较表明,与其他药物相比,可比药物的疗效略高.
- 林沃塞尔塔马布具有优化的剂量方案和有利的细胞因子释放综合征 (CRS) 概况.
结论:
- 林沃塞尔塔马布代表了RRMM治疗的重大进展.
- 需要进一步的现实世界数据来定义其在MM治疗范式中的作用.
- 该药物提供了以患者为中心的剂量和改善的安全性.
相关概念视频
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K